CD19 and precursor B-cell acute lymphoblastic leukemia: In 2014, the EMA (and the FDA in 2017) granted approval to a new CAR-T cell immunotherapy (Table 3), tisagenlecleucel (Kymriah, Novartis), which targets CD19, for the treatment of B-ALL that is refractory or has relapsed after at least two previous treatments (and in 2016 (the FDA in 2018) for refractory or relapsed large B-cell lymphoma) [97,98].